Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ID93/GLA-SE Vaccine Using an Aerosol BCG Challenge Model in Healthy Adults
NCT06670755Recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of ID93 + GLA-SE in Tuberculosis (TB) (4 arms), sponsored by University of Oxford. Primary endpoint: Safety of BCG challenge by the aerosol inhaled route at day 168. Started Dec 2024; status: recruiting.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06670755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670755.